Pritor: Uses, Dosage & Side Effects
A long-acting angiotensin II receptor blocker (ARB) containing telmisartan for the treatment of essential hypertension and reduction of cardiovascular risk in adults
Pritor (telmisartan) is a prescription-only angiotensin II receptor blocker (ARB) indicated for the treatment of essential hypertension in adults and for the reduction of cardiovascular morbidity in high-risk patients. Originally developed by Boehringer Ingelheim and co-marketed by Bayer under the Pritor name, it was one of the first ARBs approved by the European Medicines Agency (EMA) in 1998. Telmisartan binds selectively and with high affinity to the angiotensin II type 1 (AT1) receptor, preventing angiotensin II—one of the body's most potent vasoconstrictors—from exerting its effects on vascular smooth muscle, the adrenal cortex and the central nervous system. With a terminal elimination half-life of more than 20 hours, Pritor is the longest-acting drug in the ARB class and delivers smooth 24-hour blood pressure control with once-daily dosing, including during the early morning hours when the risk of cardiovascular events peaks.
Quick Facts: Pritor
Key Takeaways
- Pritor contains telmisartan, a selective angiotensin II receptor blocker (ARB) used to treat essential hypertension in adults and to reduce cardiovascular events in selected high-risk patients who cannot tolerate ACE inhibitors.
- With a terminal half-life of more than 20 hours, telmisartan provides the longest duration of action of any ARB and maintains a trough-to-peak ratio above 80%, ensuring consistent 24-hour blood pressure reduction.
- Unlike ACE inhibitors, Pritor does not elevate bradykinin levels and is therefore associated with a markedly lower incidence of persistent dry cough and angioedema—important tolerability advantages in long-term therapy.
- Pritor is contraindicated in the second and third trimesters of pregnancy, in severe hepatic impairment or biliary obstruction, and when combined with aliskiren in patients with diabetes or moderate-to-severe renal impairment.
- Typical adult dosing starts at 20–40 mg once daily and is titrated to 80 mg once daily if needed; the maximum antihypertensive effect at any given dose is generally reached within 4 to 8 weeks.
What Is Pritor and What Is It Used For?
Pritor is a branded oral formulation of telmisartan, a selective non-peptide antagonist of the angiotensin II type 1 (AT1) receptor. It was developed by Boehringer Ingelheim and first authorised in the European Union in December 1998, initially under the parallel brand names Micardis (Boehringer Ingelheim) and Pritor (marketed by Bayer Schering Pharma, later GlaxoSmithKline). Although the two products are pharmaceutically identical, Pritor continues to be distributed in a number of European markets and is widely prescribed as a well-characterised, long-acting antihypertensive.
Telmisartan belongs to the angiotensin II receptor blocker class, commonly called sartans because of their shared suffix. Drugs in this class target the renin–angiotensin–aldosterone system (RAAS), a hormonal cascade that plays a central role in regulating blood pressure, fluid balance and sodium/potassium homeostasis. The RAAS is activated when renal perfusion falls, when sodium intake is low, or when sympathetic tone rises. Renin released by the juxtaglomerular cells of the kidney cleaves circulating angiotensinogen to angiotensin I, which is then converted by angiotensin-converting enzyme (ACE) to angiotensin II. Angiotensin II is one of the most powerful vasoconstrictors known, and when it binds to the AT1 receptor it triggers a host of cardiovascular effects: arteriolar constriction (raising peripheral resistance), aldosterone secretion from the adrenal cortex (promoting sodium and water retention), sympathetic activation, thirst, antidiuretic hormone release, and trophic remodelling of the heart and vasculature.
By occupying the AT1 receptor, telmisartan prevents angiotensin II from exerting these effects regardless of where that angiotensin II was produced—the blockade is receptor-level rather than enzyme-level. This is clinically important because angiotensin II can also be generated by ACE-independent pathways, most notably through chymase in cardiac and vascular tissue. ACE inhibitors block only one of several pathways, whereas ARBs such as telmisartan block the common final step of receptor activation, producing a more complete inhibition of RAAS-mediated effects at the AT1 receptor. Because the related AT2 receptor is not blocked, angiotensin II is still free to signal through AT2, which is generally associated with vasodilation and antiproliferative effects—potentially a favourable balance.
Telmisartan also has a distinctive pharmacological feature among sartans: it is a partial agonist of the peroxisome proliferator-activated receptor gamma (PPAR-gamma), a nuclear receptor involved in glucose and lipid metabolism. At clinically relevant concentrations telmisartan stimulates PPAR-gamma to a modest extent, which has been associated in small mechanistic studies with improved insulin sensitivity, reduced triglycerides and favourable effects on adiponectin levels. This property has generated ongoing interest in telmisartan for patients with metabolic syndrome or type 2 diabetes, although the magnitude of the metabolic effect is much smaller than with dedicated PPAR-gamma agonists such as pioglitazone.
Licensed Indications
According to the European Medicines Agency Summary of Product Characteristics, Pritor is approved for two main indications in adults:
- Treatment of essential hypertension. Hypertension, defined by the European Society of Hypertension (ESH) as a sustained office blood pressure of 140/90 mmHg or higher, affects more than 1.4 billion adults worldwide according to the World Health Organization (WHO). Persistently elevated blood pressure is the single largest modifiable risk factor for stroke, ischaemic heart disease, heart failure and chronic kidney disease. Long-term randomised trials have demonstrated that ARBs including telmisartan reduce these outcomes by approximately 20–25% per 10 mmHg reduction in systolic blood pressure, an effect comparable to other first-line antihypertensive classes.
- Cardiovascular prevention in adults aged 55 years or older with manifest atherothrombotic cardiovascular disease (history of coronary artery disease, stroke or peripheral arterial disease) or type 2 diabetes mellitus with documented end-organ damage, who cannot tolerate ACE inhibitors. This indication is based on the landmark ONTARGET trial (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial), which randomised over 25,600 high-risk patients to ramipril, telmisartan or their combination. Telmisartan 80 mg daily was shown to be non-inferior to ramipril 10 mg daily for the composite primary endpoint of cardiovascular death, myocardial infarction, stroke or hospitalisation for heart failure, with a better tolerability profile.
Contemporary hypertension guidelines (2023 ESH, 2017 ACC/AHA, 2020 ISH) recommend ARBs such as telmisartan as one of several first-line options, alongside ACE inhibitors, calcium channel blockers and thiazide/thiazide-like diuretics. ARBs are often preferred as the RAAS-blocking agent of choice in patients who develop ACE inhibitor cough, in those with a prior history of angioedema (where a non-ACE-inhibitor RAAS blocker may still be considered cautiously), and in patients in whom long-duration, consistent 24-hour control is particularly important—such as those with documented morning blood pressure surge or nocturnal non-dipping patterns.
How Pritor Compares with Other Antihypertensive Classes
In terms of blood-pressure-lowering potency, telmisartan is broadly comparable with other ARBs (losartan, valsartan, candesartan, irbesartan, olmesartan) and with ACE inhibitors, calcium channel blockers and thiazide diuretics when used at equivalent doses. Its distinguishing features are pharmacokinetic rather than pharmacodynamic: the long terminal half-life of >20 hours, the high plasma protein binding that creates a stable reservoir, and the almost entirely biliary route of elimination (which means that renal impairment does not substantially affect clearance). These properties translate into a smooth, sustained blood pressure curve with little fluctuation between doses—so-called high trough-to-peak ratio—which is associated in observational studies with a greater reduction in target-organ damage than equivalent but shorter-acting drugs.
What Should You Know Before Taking Pritor?
Contraindications
Pritor must not be used in the following situations, where the risk of harm substantially outweighs any potential benefit:
- Hypersensitivity. Known allergy or previous severe reaction to telmisartan or any of the excipients in the tablet formulation. Previous angioedema on any ARB or ACE inhibitor should also be carefully assessed before initiating Pritor.
- Pregnancy (second and third trimesters). Drugs that interfere with the RAAS can cause fetal renal failure, oligohydramnios, skull ossification defects, pulmonary hypoplasia, intrauterine growth restriction and neonatal death. Pritor is not recommended at any stage of pregnancy and is strictly contraindicated from week 13 onwards.
- Biliary obstructive disorders. Because telmisartan is eliminated almost exclusively through bile, obstruction of the biliary tract (for example from gallstones or extrahepatic cholestasis) can cause dangerous accumulation of the drug and its pharmacologically inactive glucuronide metabolite.
- Severe hepatic impairment (Child-Pugh class C). Reduced first-pass metabolism and impaired biliary elimination lead to markedly increased drug exposure and unpredictable pharmacokinetics.
- Dual RAAS blockade with aliskiren in patients with diabetes mellitus or a glomerular filtration rate below 60 mL/min/1.73 m². The combination increases the risk of hyperkalaemia, acute kidney injury and symptomatic hypotension without improving outcomes, as shown in the ALTITUDE trial.
Warnings and Precautions
If you become pregnant or suspect you might be pregnant while taking Pritor, stop the medication and contact your doctor immediately. A brief interruption of treatment to arrange a safer alternative is far less harmful than continued exposure of the fetus to an ARB. Your doctor will transition you to an antihypertensive with an established safety profile in pregnancy such as labetalol, nifedipine modified-release or methyldopa.
Before initiating Pritor, certain clinical situations require particular caution and often additional monitoring:
- Volume or salt depletion. Patients who are dehydrated, on high-dose diuretics, on low-sodium diets, or who have had recent vomiting or diarrhoea are especially susceptible to first-dose hypotension. A lower starting dose of 20 mg and/or correction of fluid balance is advised.
- Bilateral renal artery stenosis or severe stenosis of a solitary kidney. Blockade of angiotensin II reduces glomerular efferent arteriole tone and can precipitate an acute fall in glomerular filtration rate, leading to acute kidney injury. Renal function should be checked before and 1–2 weeks after starting treatment in patients at risk.
- Chronic kidney disease. Although telmisartan pharmacokinetics are not substantially changed in renal impairment, patients with an eGFR below 30 mL/min/1.73 m² require closer monitoring of potassium and creatinine. Experience in haemodialysis patients is limited.
- Mild-to-moderate hepatic impairment (Child-Pugh class A or B). The daily dose should not exceed 40 mg because of increased bioavailability.
- Hyperkalaemia. ARBs blunt aldosterone-driven renal potassium excretion. Risk is higher in renal impairment, diabetes, advanced age, and when combined with potassium-sparing diuretics, potassium supplements or salt substitutes containing potassium chloride.
- Aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy. Any vasodilator can produce inappropriate reductions in blood pressure in these conditions; telmisartan should be introduced cautiously with haemodynamic monitoring.
- Primary hyperaldosteronism. Patients with an autonomous adrenal source of aldosterone generally do not respond well to RAAS-blocking agents; other strategies (such as mineralocorticoid receptor antagonism or adrenalectomy) are usually more effective.
- Ethnic differences. As a class, ARBs (like ACE inhibitors) are somewhat less effective as monotherapy in Black patients of African descent, who tend to have lower-renin hypertension. Calcium channel blockers or thiazide-type diuretics are often preferred first-line in that population, although ARBs remain effective in combination therapy.
Pregnancy and Breastfeeding
Pritor must not be used after the first trimester of pregnancy and is not recommended in the first trimester either. Multiple case series and registry studies have documented fetal complications following second- and third-trimester exposure to ARBs, including severe oligohydramnios, neonatal anuria, hypotension, hyperkalaemia and pulmonary hypoplasia. Defective calvarial ossification has been reported. First-trimester exposure appears to carry a smaller but still measurable signal for congenital malformations in observational data, although confounding by underlying hypertension makes the absolute attributable risk difficult to quantify.
Women of childbearing potential should use reliable contraception while on Pritor and should plan any intended pregnancy with their physician in advance so that therapy can be switched to an alternative regimen before conception. If an unplanned pregnancy occurs on Pritor, the drug should be stopped promptly and replaced with an antihypertensive agent such as methyldopa, labetalol or long-acting nifedipine, all of which have decades of reassuring pregnancy safety data.
There is no human data on telmisartan transfer into breast milk, but because other ARBs have been detected in the milk of lactating animals, breastfeeding is not recommended while taking Pritor, particularly in the case of preterm or newborn infants. A non-ARB alternative with known safety in lactation (for example enalapril or nifedipine) is generally preferred.
Driving and Operating Machinery
Telmisartan has no direct sedative effect, but occasional dizziness or syncope—particularly at the start of treatment or after dose increases—can impair the ability to drive or operate machinery safely. Patients should assess how the medicine affects them before undertaking tasks requiring full alertness, and should avoid driving if they feel lightheaded or unwell.
How Does Pritor Interact with Other Drugs?
Unlike many cardiovascular drugs, telmisartan does not undergo cytochrome P450 metabolism and is not a substrate, inhibitor or inducer of the major CYP isoenzymes. This means that CYP-mediated drug interactions, which plague many antihypertensives, are essentially absent with Pritor. Most clinically relevant interactions are therefore pharmacodynamic—that is, they arise when another drug either reinforces or counteracts telmisartan's blood-pressure-lowering or potassium-retaining effects—rather than pharmacokinetic. The main exception is digoxin, whose plasma levels rise modestly when telmisartan is added.
Major Interactions
The most clinically significant interactions fall into three groups: interactions that are formally contraindicated (dual RAAS blockade with aliskiren in diabetic or renally impaired patients); interactions that are not recommended (dual RAAS blockade with ACE inhibitors, concomitant lithium); and interactions that require dose adjustment or close monitoring (NSAIDs, potassium-raising agents, digoxin, diuretics). Within the NSAID class, the risk is dose- and duration-dependent: occasional short-term use of a single dose of ibuprofen or naproxen for headache is unlikely to be significant, but chronic daily NSAID use can substantially attenuate the antihypertensive effect and, in dehydrated or elderly patients, precipitate acute kidney injury (the so-called “triple whammy” of ARB + NSAID + diuretic).
| Drug / Drug Class | Type of Interaction | Clinical Consequence | Recommendation |
|---|---|---|---|
| Aliskiren | Dual RAAS blockade (pharmacodynamic) | Hypotension, hyperkalaemia, acute kidney injury | Contraindicated in diabetes or GFR < 60 mL/min/1.73 m² |
| ACE inhibitors (ramipril, enalapril, lisinopril, perindopril) | Dual RAAS blockade | Syncope, hyperkalaemia, renal dysfunction without outcome benefit (ONTARGET) | Generally not recommended; avoid combination |
| Lithium | Reduced renal lithium clearance | Lithium toxicity: tremor, confusion, nausea, arrhythmia | Avoid if possible; monitor lithium concentrations closely |
| NSAIDs (ibuprofen, naproxen, diclofenac, COX-2 inhibitors) | Pharmacodynamic antagonism | Reduced antihypertensive effect; increased risk of acute kidney injury, especially with diuretic co-therapy | Use cautiously; monitor BP and renal function; maintain hydration |
| Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene) | Additive potassium retention | Dangerous hyperkalaemia | Monitor serum potassium; avoid routine combination outside of heart-failure indications |
| Potassium supplements / salt substitutes | Additive potassium load | Hyperkalaemia | Avoid unless clearly indicated; check potassium |
| Digoxin | Telmisartan raises digoxin Cmax and trough by ~20–50% | Potential digoxin toxicity (nausea, arrhythmia, visual disturbance) | Measure digoxin level on starting, changing dose, or stopping Pritor |
| Thiazide and loop diuretics | Additive blood pressure lowering (intended, but can be excessive) | First-dose hypotension, especially when volume-depleted | Start at lowest telmisartan dose; correct volume status first |
| Corticosteroids (systemic) | Sodium and water retention | Reduced antihypertensive effect | Monitor blood pressure; adjust dose if necessary |
Minor Interactions
Single-dose pharmacokinetic studies have found no clinically meaningful interactions between telmisartan and paracetamol, amlodipine, glibenclamide, simvastatin, warfarin, hydrochlorothiazide or ibuprofen. Telmisartan does not significantly affect warfarin pharmacokinetics and does not alter the international normalised ratio (INR) in clinical studies. Alcohol does not have a direct pharmacokinetic interaction with telmisartan but can enhance its blood-pressure-lowering effect and exaggerate dizziness, particularly when standing up, so moderate consumption is advised.
Grapefruit juice, which affects many CYP3A4-dependent drugs, has no clinically significant effect on telmisartan exposure. Similarly, telmisartan does not have appreciable effects on the metabolism of other commonly co-prescribed drugs such as statins, metformin, oral anticoagulants or hormonal contraceptives.
Even though telmisartan has a favourable interaction profile, you should provide your prescriber and pharmacist with a full list of all prescription medicines, over-the-counter products (including NSAIDs such as ibuprofen), herbal preparations (especially liquorice root, which can raise blood pressure), and dietary supplements (especially potassium-containing products and salt substitutes). This is the simplest and most effective way to avoid unexpected drug-drug interactions.
What Is the Correct Dosage of Pritor?
Pritor is taken orally as a once-daily tablet. It can be taken with or without food—absorption of telmisartan is reduced by about 6% when taken with food, which is not clinically relevant. Consistency is more important than exact timing: taking the tablet at the same time each day, whether morning or evening, helps maintain steady plasma concentrations and makes adherence easier. The tablet should be swallowed whole with a glass of water and should not be crushed, split or chewed, because the 20 mg formulation is not scored for this purpose.
Adults
| Indication | Starting Dose | Usual Maintenance Dose | Maximum Dose |
|---|---|---|---|
| Essential hypertension | 20–40 mg once daily | 40–80 mg once daily | 80 mg once daily |
| Cardiovascular prevention (ONTARGET indication) | 80 mg once daily (full dose) | 80 mg once daily | 80 mg once daily |
| Hepatic impairment (mild-moderate) | 20 mg once daily | 20–40 mg once daily | 40 mg once daily |
| Volume-depleted patients / high-dose diuretic therapy | 20 mg once daily (after correcting volume status) | Titrate according to BP | 80 mg once daily |
For essential hypertension, most patients begin with 40 mg once daily. If this fails to achieve the target blood pressure (generally <140/90 mmHg in most adults, or <130/80 mmHg in high-risk groups according to more recent guidelines), the dose can be doubled to 80 mg, or a second agent can be added. The 20 mg starting strength is reserved for patients in whom cautious initiation is preferred: elderly adults over 75 years, those on high-dose diuretics, and those with mild-to-moderate hepatic impairment. Because telmisartan has a slow onset of maximal effect, dose titration should not be performed more frequently than every 4 weeks.
For cardiovascular prevention in eligible patients aged 55 and older, the licensed dose is 80 mg once daily from the outset, mirroring the protocol of the ONTARGET trial. Lower doses have not been shown to achieve the same cardiovascular protection. Patients starting at 80 mg should have their blood pressure and renal function rechecked 1–2 weeks after initiation, and any concurrent antihypertensives may need to be down-titrated to avoid symptomatic hypotension.
Children and Adolescents
The safety and efficacy of Pritor in children and adolescents below 18 years have not been formally established, and the SmPC explicitly does not recommend its use in this age group. Paediatric hypertension should be managed by specialists using agents with established paediatric dosing and safety data, such as enalapril, losartan or amlodipine.
Elderly Patients
No routine dose adjustment is required on the basis of age alone; telmisartan exposure is not meaningfully altered in older adults. However, elderly patients—particularly those above 80 years or those with multiple comorbidities—are more susceptible to orthostatic hypotension, falls, hyperkalaemia and acute kidney injury. A cautious start at 20 mg once daily and slower uptitration is sensible in frail patients, with assessment of postural blood pressure, serum creatinine and potassium 1–2 weeks after each dose change.
Renal and Hepatic Impairment
Because telmisartan is almost entirely eliminated through the hepatobiliary route, dose adjustment is not required in mild-to-moderate renal impairment, and telmisartan is not removed by haemodialysis. In patients with an eGFR below 30 mL/min/1.73 m², closer monitoring of potassium and creatinine is recommended, especially in the first 1–2 weeks. In mild-to-moderate hepatic impairment (Child-Pugh class A or B) the daily dose must not exceed 40 mg. In severe hepatic impairment (Child-Pugh class C) or biliary obstructive disease, Pritor is contraindicated.
Missed Dose
If you miss a dose, take it as soon as you remember on the same day. If you only remember the next day, skip the missed dose entirely and take your next scheduled tablet at the usual time. Do not double the dose to compensate. Because telmisartan has such a long duration of action, missing a single dose rarely causes a clinically significant rise in blood pressure, but repeated missed doses can compromise control. If forgetting is a recurrent problem, consider using a pillbox with a daily alarm, linking the dose to a daily routine such as brushing teeth, or using a smartphone reminder app.
Overdose
Experience with intentional telmisartan overdose is limited. The expected features of overdose are hypotension, compensatory tachycardia, and possibly bradycardia if there is increased parasympathetic tone. Doses of up to 160 mg have been administered in clinical studies without serious adverse events, but much higher intentional overdoses could in principle cause severe hypotension and renal hypoperfusion.
In case of known or suspected overdose, the patient should be placed supine with legs elevated and medical help obtained urgently. Treatment is supportive: intravenous normal saline for hypotension, atropine for symptomatic bradycardia, and close monitoring of blood pressure, heart rate, renal function and serum electrolytes. Activated charcoal may be considered within 1 hour of ingestion if airway protection allows. Haemodialysis is not effective for telmisartan because of its high plasma protein binding.
If you or someone else has taken a significantly larger dose of Pritor than prescribed, contact your local poison control centre or emergency services immediately. Symptoms can include severe dizziness, fainting, rapid or slow heartbeat, and extreme weakness. Lie down with legs raised while waiting for medical help and do not attempt to drive.
What Are the Side Effects of Pritor?
In pooled analyses of randomised trials, the frequency of adverse events with telmisartan was not statistically different from placebo, reflecting the excellent tolerability of this agent. In the head-to-head ONTARGET trial, telmisartan caused significantly less cough (1.1% vs 4.2%) and angioedema (0.1% vs 0.3%) than the ACE inhibitor ramipril, while overall discontinuation rates due to adverse events were comparable. Telmisartan tends to be particularly well tolerated in patients who have previously failed ACE inhibitor therapy because of cough.
The following adverse effects have been reported in clinical trials and post-marketing surveillance. They are classified by MedDRA frequency convention (“very common” ≥1/10; “common” ≥1/100 to <1/10; “uncommon” ≥1/1,000 to <1/100; “rare” ≥1/10,000 to <1/1,000; “not known” cannot be estimated).
Uncommon
May affect up to 1 in 100 people
- Upper respiratory tract infection (pharyngitis, sinusitis)
- Urinary tract infection, cystitis
- Anaemia
- Hyperkalaemia (elevated potassium)
- Insomnia, anxiety, depression
- Dizziness, vertigo
- Syncope (fainting)
- Bradycardia (slow heart rate)
- Hypotension, including orthostatic hypotension
- Cough, dyspnoea (shortness of breath)
- Abdominal pain, diarrhoea, dyspepsia, flatulence
- Pruritus, rash, hyperhidrosis
- Back pain, myalgia, muscle spasms
- Renal impairment, including acute renal failure
- Chest pain, asthenia (weakness, fatigue)
- Increased blood creatinine
Rare
May affect up to 1 in 1,000 people
- Sepsis (in ONTARGET, rare but with occasional fatal outcome)
- Thrombocytopenia (low platelet count)
- Eosinophilia
- Hypersensitivity reactions: anaphylaxis, angioedema
- Hypoglycaemia (mainly in patients with diabetes)
- Visual disturbance
- Tachycardia
- Hepatic function abnormalities / liver disorders
- Erythema, drug eruption, toxic skin eruption
- Arthralgia, tendinitis and tendon pain
- Flu-like illness
- Elevated hepatic enzymes (AST, ALT)
- Decreased haemoglobin
Not Known
Frequency cannot be estimated from available data
- Erythrocytosis (raised red cell count)
- Hyperuricaemia (raised uric acid)
- Interstitial lung disease (very rare case reports)
Several adverse effects deserve particular comment. First-dose hypotension is most likely in patients who are volume-depleted from high-dose diuretic therapy, salt restriction or recent illness; correcting the underlying problem and starting at 20 mg usually prevents this. Hyperkalaemia becomes more common as renal function declines and when combined with potassium-sparing diuretics, NSAIDs, trimethoprim or potassium supplements; routine potassium monitoring is therefore recommended at baseline, 1–2 weeks after initiation, after dose changes, and annually thereafter. Acute kidney injury is a recognised but reversible effect that typically occurs when telmisartan is started in patients with occult renal artery disease, severe heart failure, or during intercurrent illness with dehydration.
Stop taking Pritor and seek immediate medical attention if you experience any of the following: swelling of the face, lips, tongue or throat (angioedema); difficulty breathing or swallowing; severe skin reaction with blistering or peeling; markedly reduced urine output; sudden weakness, irregular heartbeat or muscle cramps (possible hyperkalaemia); or severe, persistent dizziness or fainting. These are uncommon but potentially serious events that require urgent evaluation.
All suspected adverse reactions to Pritor should be reported to your national pharmacovigilance scheme (for example the Yellow Card Scheme in the United Kingdom, the FDA MedWatch programme in the United States, or EudraVigilance in the European Union). Reporting by patients and healthcare professionals plays an essential role in detecting rare or delayed-onset adverse effects that may not have been identified during pre-marketing trials.
How Should You Store Pritor?
Telmisartan is highly hygroscopic, meaning it absorbs moisture readily. For this reason, Pritor tablets are supplied in aluminium blisters with desiccant properties, and the manufacturer explicitly recommends that the tablets remain in the original blister strip until immediately before administration. Storing loose tablets in a weekly pillbox for more than 7 days, or in a humid environment such as a bathroom cabinet, can compromise tablet integrity and may reduce bioavailability.
The medication should be stored at a temperature below 25°C (77°F) in a dry place away from direct sunlight. No special refrigeration is required; in fact, refrigeration is unnecessary and may actually expose tablets to condensation when the pack is moved between cold and warm environments. A bedside drawer or a dedicated medicine cabinet in a cool, dry room is ideal.
Keep Pritor out of the sight and reach of children at all times. Accidental paediatric ingestion of even a single adult antihypertensive tablet can cause severe hypotension requiring emergency medical treatment. If a child ingests Pritor, contact your local poison control centre immediately, even if the child appears well, because symptoms of hypotension can be delayed by several hours.
Do not use Pritor after the expiry date stated on the carton and blister. The expiry date refers to the last day of the stated month. Do not dispose of unused or expired medication in household waste or wastewater, which can contribute to pharmaceutical contamination of the environment; instead, return unwanted medication to a community pharmacy take-back scheme, which exists in most countries. Many pharmacies accept unused medicines at any time, without a prescription or explanation.
What Does Pritor Contain?
Active Ingredient
Each Pritor tablet contains telmisartan 20 mg as the sole active pharmaceutical ingredient. Telmisartan (chemical name 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid; molecular formula C33H30N4O2; molecular weight 514.63 g/mol) is a white to slightly yellowish crystalline solid that is practically insoluble in water at neutral pH. Because of this poor solubility, specialised formulation technology is required to achieve adequate oral bioavailability, which is why the excipient list of the tablet is carefully chosen.
Inactive Ingredients (Excipients)
In addition to telmisartan, the Pritor 20 mg tablet typically contains the following excipients, each serving a defined pharmaceutical purpose:
- Sodium hydroxide — used in very small amounts as a pH-adjusting agent. In combination with meglumine it helps solubilise telmisartan during granulation.
- Meglumine — functions as an alkalising and solubilising agent, forming a salt with telmisartan that markedly improves its dissolution profile and absorption.
- Povidone (K25) — a water-soluble polymer used as a binder to hold the tablet together and as a solubility enhancer for telmisartan.
- Sorbitol (E420) — a polyol used as a filler and diluent. Patients with the rare inherited disorder hereditary fructose intolerance should avoid Pritor or use it only with specialist advice, because sorbitol is metabolised to fructose.
- Magnesium stearate — a lubricant added at low concentration to prevent the powder blend from sticking to tablet-press tooling during compression.
Depending on the country and manufacturing batch, tablets may have slightly different visual characteristics; Pritor 20 mg is typically described as a white to slightly yellowish, oblong-shaped tablet. Each strength (20 mg, 40 mg and 80 mg) is visually distinct to help patients and pharmacists distinguish between doses. Always check that the appearance of the tablet matches that described in the patient information leaflet supplied with your prescription.
The product is marketed in blister packs of various sizes (typically 14, 28, 30, 56, 84 or 98 tablets). Not all pack sizes may be available in every country. The EMA marketing authorisation holder historically listed on the Pritor packaging is Bayer Pharma AG (later Bayer AG), although marketing rights and distribution have changed over the years.
Frequently Asked Questions About Pritor
Pritor (telmisartan) is used to treat essential high blood pressure (hypertension) in adults, and to reduce the risk of cardiovascular events such as heart attack and stroke in patients aged 55 or older with significant cardiovascular disease or diabetes with organ damage who cannot tolerate ACE inhibitors. It belongs to the angiotensin II receptor blocker (ARB) class and is taken as a once-daily tablet.
Yes, the active ingredient and strengths are identical. Pritor and Micardis were co-branded products launched by Boehringer Ingelheim and Bayer following the original EU approval of telmisartan in 1998. Since patent expiry in most regions, generic telmisartan tablets are also available and are bioequivalent to both branded products. The choice between brands is largely a matter of local reimbursement and availability rather than clinical difference.
Either can work because telmisartan's long half-life provides continuous 24-hour coverage. Many clinicians suggest morning dosing because it aligns the blood-pressure-lowering effect with the early morning surge when cardiovascular events are most common. However, if you experience troublesome daytime dizziness you may be asked to switch to evening dosing. The most important rule is consistency: take it at the same time every day, whether morning or evening, to maintain stable plasma levels.
Moderate alcohol intake is usually acceptable, but alcohol itself lowers blood pressure acutely and raises it with chronic heavy use. When combined with Pritor, alcohol can amplify dizziness and orthostatic hypotension, especially when standing up quickly. Current guidelines for the general population recommend no more than 14 units of alcohol per week, spread over several days, with several alcohol-free days. Avoid binge drinking. If you have liver disease, consult your doctor before drinking any alcohol while on telmisartan.
Pritor is not associated with clinically significant weight gain. In controlled trials body weight was similar in telmisartan and placebo groups. Unlike beta-blockers and some thiazide diuretics, ARBs have a neutral metabolic profile and may even slightly improve insulin sensitivity. If you experience unexplained weight gain on Pritor, other causes such as fluid retention, dietary change or another medication should be considered.
ARBs including telmisartan are recommended first-line agents in patients with type 2 diabetes who have albuminuria, because they reduce the progression of diabetic kidney disease beyond what would be expected from blood pressure reduction alone. Evidence in telmisartan specifically comes from the ONTARGET trial and several smaller renal-outcome studies. It is important to understand that RAAS blockade can initially cause a 10–20% rise in serum creatinine; this is expected, usually reversible, and does not mean the drug is damaging the kidneys. However, a larger rise, a fall in eGFR of more than 30%, or severe hyperkalaemia should prompt dose reduction or discontinuation.
Yes. Most patients with hypertension ultimately need two or more agents to reach target. Pritor combines well with thiazide or thiazide-like diuretics (hydrochlorothiazide, indapamide, chlortalidone) and with calcium channel blockers (amlodipine). These are the combinations most strongly supported by outcomes trials and guidelines. Fixed-dose combination tablets containing telmisartan plus hydrochlorothiazide (e.g. PritorPlus) or telmisartan plus amlodipine exist and can improve adherence. However, Pritor should not routinely be combined with ACE inhibitors or with aliskiren (contraindicated in diabetes or renal impairment), since dual RAAS blockade increases risk without improving outcomes.
References
- European Medicines Agency (EMA). Pritor – Summary of Product Characteristics (SmPC). Last updated 2025. Available from: www.ema.europa.eu
- Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559. doi:10.1056/NEJMoa0801317 (ONTARGET Trial)
- Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial (TRANSCEND). Lancet. 2008;372(9644):1174–1183.
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071. doi:10.1097/HJH.0000000000003480
- World Health Organization (WHO). Guideline for the pharmacological treatment of hypertension in adults. Geneva: WHO; 2021. Available from: www.who.int
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127–e248.
- Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204–2213. (ALTITUDE Trial)
- British National Formulary (BNF). Telmisartan. National Institute for Health and Care Excellence (NICE). Available from: bnf.nice.org.uk
- Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43(5):993–1002.
- Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334–1357.
- Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res. 2000;28(4):149–167.
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. Kidney Int. 2024;105(4S):S117–S314.
Editorial Team
Medical Content
Written by the iMedic Medical Editorial Team – specialists in cardiology, clinical pharmacology and internal medicine with combined experience across academic and community practice.
Medical Review
Reviewed by the iMedic Medical Review Board – an independent panel of board-certified physicians evaluating content against ESH, ACC/AHA, WHO and NICE guidelines.
Evidence Standard
All clinical claims are graded using the GRADE framework and are based on Evidence Level 1A – systematic reviews and meta-analyses of randomised controlled trials where available.
Editorial Independence
No pharmaceutical company funding, no commercial sponsorship and no advertising. Editorial decisions follow strict conflict-of-interest and correction policies published on our editorial standards page.
Published: | Last medical review: | Next scheduled review: